Abstract 27P
Background
HER2-low breast cancers are defined as having an immunohistochemical (IHC) score of 1+, or 2+ with nonamplified in-situ hybridization (ISH). The biological features of HER2-low-expressing triple-negative breast cancers (TNBC) remain unclear. This study aimed to reveal the TNBC molecular subtypes with both HER2-low and HER2-zero using mRNA profiling and identify the biological characteristics of HER2-low in TNBC.
Methods
We analyzed 64 cases of TNBCs collected from four medical centers. Molecular subtypes of TNBC were identified, and comprehensive expression analysis was performed. The correlation between mRNA expression and HER2 expression in protein IHC was also analyzed.
Results
Of the 64 cases, 30 had HER2-zero, and 32 had HER2-low-positive. Luminal androgen receptor (LAR) subtype was more common in the HER2-low group (P=0.0017). Table: 27P
TNBC molecular subtype compared with HER2-low and HER2-zero
HER2-low | HER2-zero | p-value | |
BL1 | 14 (44%) | 13 (43%) | |
BL2 | 2 (6%) | 3 (10%) | |
LAR | 11 (34%) | 1 (3%) | 0.00017 |
M | 1 (3%) | 9 (30%) | |
N/A | 4 (13%) | 4 (13%) |
The HER2-low group had significantly higher ERBB2 expression than the HER2-zero group (p=0.05). In 20% of the HER2-zero group, HER2 expression was detected at the mRNA expression level. When performing clustering analysis between HER2-low and HER2-zero, among the top 10 genes highly expressed in HER2-low, genes highly expressed in hormone-dependent tumors such as FOXA1 and genes involved in metabolic process were found. Interestingly, somatic BRCA1 expression was significantly higher in the HER2-zero group.
Conclusions
The HER2-low group had molecular features that were distinct from the HER2-zero group and were more similar to the LAR subtype. Evaluating HER2 expression by mRNA may identify HER2-low breast cancers that cannot be identified at the protein level in IHC, which may allow for more patients with TNBC to receive effective anti-HER2 drugs. However, further studies are needed to confirm these findings.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Oncocyte.
Disclosure
N. Hayashi: Financial Interests, Personal, Speaker’s Bureau: Eli Lily, AstraZeneca, Taiho, Eizai, Novartis, Pfizer, Chugai; Financial Interests, Personal, Research Funding: AstraZeneca, MSD, Konica Minolta Japan, Chugai. S. Nakamura: Financial Interests, Institutional, Funding: AstraZeneca, Daiichi Sankyo; Financial Interests, Personal, Speaker’s Bureau: AstraZeneca, Daiichi Sankyo, Chugai. R. Seitz, D. Hout: Other, Personal, Member: Oncocyte. N.T. Ueno: Financial Interests, Personal, Advisory Board: Daiichi Sankyo. H. Masuda: Financial Interests, Personal, Speaker’s Bureau: Sysmex, Eli Lily, Pfizer, Chugai. All other authors have declared no conflicts of interest.
Resources from the same session
204P - A radiomics strategy based on CT intra-tumoral and peritumoral regions for preoperative prediction of neoadjuvant chemoradiotherapy for esophageal cancer
Presenter: zhiyang li
Session: Poster Display
Resources:
Abstract
205TiP - IMPACT: Randomized, multicenter, phase III study evaluating the efficacy of immunotherapy (atezolizumab) plus anti-VEGF therapy (bevacizumab) in combination with transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma (HCC)
Presenter: Tatsuya Yamashita
Session: Poster Display
Resources:
Abstract
206TiP - SIERRA: A phase IIIb, single-arm, multicentre study of tremelimumab plus durvalumab for first-line treatment of advanced unresectable hepatocellular carcinoma
Presenter: Stephen Chan
Session: Poster Display
Resources:
Abstract
207TiP - A two-arm randomized open-label prospective design superiority phase III clinical trial to compare the efficacy of docetaxel-oxaliplatin-capecitabine/ 5 -fluorouracil (DOC/F) followed by docetaxel versus CAPOX/mFOLFOX-7 in advanced gastric cancers
Presenter: Prabhat Bhargava
Session: Poster Display
Resources:
Abstract
212P - Mutational landscape and characteristics of ERBB2 in urothelial carcinoma
Presenter: Mingwei Li
Session: Poster Display
Resources:
Abstract
213P - Prognostic significance of absolute lymphocyte count in patients with metastatic renal cell carcinoma treated with first-line combination immunotherapies: Results from the International metastatic renal cell carcinoma database consortium (IMDC)
Presenter: Kosuke Takemura
Session: Poster Display
Resources:
Abstract
214P - Development and prospective validation of a multiplex RNA urine test for noninvasive detection and surveillance of urothelial carcinoma
Presenter: Hua Xu
Session: Poster Display
Resources:
Abstract
215P - Real-world outcomes of first-line tislelizumab plus axitinib in patients with metastatic non-clear cell renal cell carcinoma (mnccRCC)
Presenter: Pei Dong
Session: Poster Display
Resources:
Abstract
216P - Preliminary efficacy and safety results from ‘ReBirth’: A phase II study of risk-based bladder-sparing therapy for MIBC
Presenter: Yijun Shen
Session: Poster Display
Resources:
Abstract
217P - Conditional reprogramming of urine-derived bladder cancer cells: A model for precision medicine
Presenter: Yu Dong
Session: Poster Display
Resources:
Abstract